China Biologic Products Holdings, Inc.
CBPO
CBPO was delisted on the 20th of April, 2021.
86 hedge funds and large institutions have $1.48B invested in China Biologic Products Holdings, Inc. in 2018 Q1 according to their latest regulatory filings, with 12 funds opening new positions, 30 increasing their positions, 26 reducing their positions, and 17 closing their positions.
15% more repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 26
2% more capital invested
Capital invested by funds: $1.45B → $1.48B (+$24.6M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
8% less funds holding
Funds holding: 93 → 86 (-7)
12.01% less ownership
Funds ownership: 66.96% → 54.95% (-12%)
29% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 17
67% less call options, than puts
Call options by funds: $2.42M | Put options by funds: $7.32M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VAM
Vontobel Asset Management
New York
|
+$63.5M |
| 2 |
Capital Research Global Investors
Los Angeles,
California
|
+$56.2M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$43.2M |
| 4 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$41.4M |
| 5 |
BlackRock
New York
|
+$20M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
-$75.7M |
| 2 |
Artisan Partners
Milwaukee,
Wisconsin
|
-$45.2M |
| 3 |
ICP
Indus Capital Partners
New York
|
-$26M |
| 4 |
AllianceBernstein
Nashville,
Tennessee
|
-$22.8M |
| 5 |
Fidelity International
Hamilton,
Bermuda
|
-$22.5M |
CBPO Hedge Fund Activity: Q1 2018 in Review
86 of the 4,373 institutional investors tracked by Wall St. Rank reported a position in China Biologic Products Holdings, Inc. (CBPO) for Q1 2018, worth a combined $1.48B — up 1.7% from $1.45B a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of CBPO and 12 opened new positions — a net loss of 5 holders — while 26 trimmed existing stakes and 30 added.
The largest buyer was Vontobel Asset Management, adding an estimated $63.5M. The largest seller was Invesco, cutting an estimated $75.7M.
- 86 institutional investors held China Biologic Products Holdings, Inc. (CBPO) as of Q1 2018, down from 93 in Q4 2017.
- Funds reported $1.48B of China Biologic Products Holdings, Inc. stock for Q1 2018, up 1.7% quarter-over-quarter.
- 12 funds opened new China Biologic Products Holdings, Inc. positions in Q1 2018 and 17 closed out, a net change of -5 holders.
- The largest China Biologic Products Holdings, Inc. buyer in Q1 2018 was Vontobel Asset Management, an estimated $63.5M added.
- The largest China Biologic Products Holdings, Inc. seller in Q1 2018 was Invesco, an estimated $75.7M sold.
Based on aggregated 13F filings for Q1 2018.